New research reviews the evidence behind the benefits of drug microdosing and suggests that more “rigorous, placebo-controlled clinical studies” are necessary.

 

The practice of microdosing — taking small doses of psychedelic drugs such as psilocybin or DMT to improve mental health, well-being, or productivity — has gained increasing attention in recent years.

 

Reports from health and science publications have highlighted studies suggesting that substances such as magic mushrooms and Ayahuasca may help treat certain mental health disorders, sometimes while avoiding the side effects of more conventional treatments.

 

Anecdotal evidence shared in online forums also describes additional benefits. Users often report improvements in energy, mood, cognition, concentration, stress management, creativity, spiritual awareness, productivity, language abilities, relationships, and visual perception.

 

The practice has also gained popularity after prominent figures, including Steve Jobs, spoke about the potential benefits of microdosing lysergic acid diethylamide (LSD) for creativity and cognition.

 

However, questions remain about what microdosing actually involves and whether scientific evidence supports the growing enthusiasm. New research published in the Journal of Psychopharmacology attempts to address these questions.

 

Professor David Nutt, who holds the Edmond J. Safra Chair in Neuropsychopharmacology at Imperial College London in the United Kingdom, is the senior author of the review.

 

Prof. Nutt explains the motivation for the study, saying that despite the increasing interest in microdosing, there is still no scientific consensus on what the practice actually means. Researchers do not yet agree on what qualifies as a “micro” dose, how frequently it should be taken, or whether it produces measurable health effects.

 

To address these uncertainties, Prof. Nutt and his team reviewed existing research and proposed three components that could help define microdosing.

 

The first component is the use of a very low dose that remains below the perceptual threshold and does not impair normal functioning. The second involves a procedure that includes multiple dosing sessions. The third component is the intention to improve well-being and enhance cognitive or emotional processes.

 

Researchers also note that experts generally define a microdose as roughly one-tenth to one-twentieth of a typical recreational dose. However, this measurement can vary depending on the substance being used.

 

The researchers also caution that the frequency of microdosing can vary widely. Some individuals may take small doses for several days in a row, while others may only dose on certain weekdays. In addition, the strength and potency of psychedelic substances can differ depending on their source.

 

The review primarily focused on psilocybin, the active compound found in magic mushrooms. The researchers selected psilocybin because it is currently one of the psychedelic substances closest to becoming an approved clinical treatment.

 

Even so, the authors emphasize that there are still not enough controlled clinical trials comparing the effects of psilocybin to a placebo.

 

Regarding safety, the researchers highlight that studies involving humans and animals have not yet provided sufficient evidence to demonstrate the long-term safety or benefits of regular psilocybin microdosing. Some studies have also suggested potential cardiovascular risks.

 

When examining potential behavioral benefits — such as improved focus or enhanced creativity — the researchers found that existing evidence remains mixed.

 

Some early research suggests that psilocybin interacts with serotonin receptors in the brain. Serotonin is often referred to as the “happiness neurotransmitter” and plays an important role in learning and memory. The reviewers suggest that reported improvements in mood or concentration may be linked to this mechanism.

 

However, the researchers stress that rigorous placebo-controlled clinical trials using low doses of psilocybin are needed to determine whether the claims made by microdosing advocates are supported by scientific evidence.

 

The study’s first author, Dr. Kim Kuypers from Maastricht University in the Netherlands, notes that the review comes at an important time because media coverage has generated significant optimism about the potential effects of microdosing.

 

Dr. Kuypers warns that people may feel encouraged by these reports to try microdosing themselves, even though there is currently limited scientific proof that the practice can effectively treat symptoms.

 

The researchers hope that their review will highlight the need for further investigation and encourage new research into the potential benefits and risks of microdosing.

 

Professor Nutt adds that scientists working in psychedelic research frequently receive questions from the media about microdosing. He concludes that the review aims to provide a clearer framework that can guide future research and help answer these questions more definitively.